Jan Booij

Jan Booij's AcademicInfluence.com Rankings

Jan Booij

Biology

#12439

World Rank

#15914

Historical Rank

Neuroscience

#2087

World Rank

#2145

Historical Rank

biology Degrees

Download Badge

Biology

Jan Booij's Degrees

PhD Neuroscience University of Amsterdam
Bachelors Biology University of Amsterdam

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Jan Booij Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan Booij's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gender differences in Parkinson’s disease (2006) (718)
Idiopathic hyposmia as a preclinical sign of Parkinson's disease (2004) (717)
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study (2007) (543)
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group (2000) (513)
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 (2009) (461)
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. (1997) (407)
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell (2001) (292)
Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers (2000) (281)
EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 (2010) (280)
Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons (2001) (261)
Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations (2001) (254)
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism (2001) (254)
Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission (2000) (217)
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. (1998) (209)
SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* (2012) (207)
Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. (2001) (206)
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. (2000) (202)
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT (2009) (200)
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis (2012) (196)
Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism (1999) (188)
Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease (2017) (175)
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects (2011) (169)
Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT (1997) (160)
Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3 (2008) (154)
Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs (2008) (152)
The Acute and Chronic Effects of MDMA (“Ecstasy”) on Cortical 5-HT2A Receptors in Rat and Human Brain (2002) (146)
One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. (1999) (137)
Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. (2007) (135)
Evaluation of high-resolution pinhole SPECT using a small rotating animal. (2001) (133)
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2 (2009) (132)
Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease (1998) (132)
Structural, functional and molecular imaging of the brain in primary focal dystonia—A review (2011) (129)
Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. (2009) (128)
Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: A head-to-head comparison with 15O H2O positron emission tomography (2014) (126)
Effects of psychotherapy on regional cerebral blood flow during trauma imagery in patients with post-traumatic stress disorder: a randomized clinical trial (2007) (125)
Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies (2009) (124)
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. (2000) (124)
The role of dopamine in human addiction: from reward to motivated attention. (2005) (123)
Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder (2004) (121)
[123I]FP‐CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP‐lesioned monkeys (1997) (120)
Neuroimaging essentials in essential tremor: A systematic review (2014) (120)
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. (2003) (118)
MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. (2000) (113)
Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease (2009) (106)
Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. (2008) (104)
Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males (2008) (102)
Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease (2014) (99)
[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease (2001) (97)
Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. (2012) (96)
Deep Brain Stimulation Induces Striatal Dopamine Release in Obsessive-Compulsive Disorder (2014) (94)
The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. (1992) (92)
Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender (2004) (91)
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review (2015) (89)
VECTor: A Preclinical Imaging System for Simultaneous Submillimeter SPECT and PET (2013) (89)
[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease (2003) (87)
Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database (2013) (86)
Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? (2014) (86)
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT (2001) (85)
Preclinical (premotor) Parkinson’s disease (2000) (85)
Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. (2005) (85)
Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects (2006) (85)
Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters (1997) (85)
Early and Presenting Symptoms of Dementia with Lewy Bodies (2011) (84)
Serotonin transporter binding with [123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender (2009) (81)
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT (2012) (80)
Impulsivity in adult ADHD patients with and without cocaine dependence. (2013) (80)
Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]β-CIT SPECT study – preliminary report (2001) (79)
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease (2005) (79)
A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users (2007) (78)
Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users (2006) (76)
Validation of [123I]β-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram (2005) (75)
Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications (2004) (74)
Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity (2014) (73)
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. (1998) (72)
Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease (2014) (69)
Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography (1997) (68)
Imaging of dopamine transporters with [123I]FP‐CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease (2001) (68)
Striatal dopamine regulates systemic glucose metabolism in humans and mice (2018) (68)
The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies. (2017) (66)
Disrupted Dopaminergic Neurotransmission in 22q11 Deletion Syndrome (2008) (66)
FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder (2017) (65)
High fat/carbohydrate ratio but not total energy intake induces lower striatal dopamine D2/3 receptor availability in diet-induced obesity (2013) (65)
Amantadine as N-methyl-d-aspartic acid receptor antagonist: new possibilities for therapeutic applications? (1992) (63)
Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study (2006) (63)
Reduced striatal D2 receptor binding in myoclonus–dystonia (2009) (62)
Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls (2014) (62)
Value of Semiquantitative Analysis for Clinical Reporting of 123I-2-β-Carbomethoxy-3β-(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropane SPECT Studies (2013) (59)
The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review (2010) (59)
The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance (2005) (58)
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia (2005) (58)
EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2 (2010) (58)
Striatal dopaminergic modulation of reinforcement learning predicts reward—oriented behavior in daily life (2017) (58)
Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy (2009) (58)
Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods. (2015) (57)
Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease (2005) (57)
Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. (1999) (56)
Biological Mechanisms Whereby Social Exclusion May Contribute to the Etiology of Psychosis: A Narrative Review (2017) (56)
Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography (2002) (55)
[123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies (2016) (55)
SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. (2007) (55)
Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. (2006) (54)
Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study (2008) (54)
Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder (2009) (52)
Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach (2001) (52)
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures (2008) (52)
Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia. (2014) (51)
Co‐occurrence of early‐onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging (2010) (50)
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database (2011) (50)
No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers (2013) (47)
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia (1999) (46)
Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region. (2013) (46)
Free‐Choice and No‐Choice High‐Fat Diets Affect Striatal Dopamine D2/3 Receptor Availability, Caloric Intake, and Adiposity (2012) (46)
Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia (2001) (44)
Striatal dopamine receptor binding in morbidly obese women before and after gastric bypass surgery and its relationship with insulin sensitivity (2014) (44)
Cerebral impairment in chronic solvent‐induced encephalopathy (2008) (43)
Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. (1999) (42)
[123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication (2000) (41)
Diagnostic Performance of the Visual Reading of 123I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia (2017) (40)
Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment (2011) (39)
Association of central serotonin transporter availability and body mass index in healthy Europeans (2014) (38)
[123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls (1997) (38)
(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study (2013) (37)
Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study (2012) (37)
Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications (2013) (37)
Validity of [123I]β‐CIT SPECT in detecting MDMA‐induced serotonergic neurotoxicity (2002) (37)
[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods (2017) (36)
Movies of dopamine transporter occupancy with ultra-high resolution focusing pinhole SPECT (2007) (36)
Assessing the Optimal Time Point for the Measurement of Extrastriatal Serotonin Transporter Binding with 123I-FP-CIT SPECT in Healthy, Male Subjects (2012) (35)
The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (2016) (35)
Infusion of donor feces affects the gut–brain axis in humans with metabolic syndrome (2020) (35)
Striatal dopamine D2/3 receptor availability increases after long-term bariatric surgery-induced weight loss (2016) (35)
Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis (2013) (34)
Neurotoxic effects of ecstasy on the thalamus (2008) (34)
The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies (2016) (34)
Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease. (1995) (33)
In vitro and ex vivo storage phosphor imaging of short-living radioisotopes (2008) (33)
Low striatal D2 receptor binding as assessed by [123I]IBZM SPECT in patients with writer's cramp. (1997) (33)
Analysis of Extrastriatal 123I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases (2017) (33)
IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. (1997) (32)
Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia – relationship with COMT Val108/158 Met polymorphism, gender and symptomatology (2011) (32)
Serotonin transporter binding and anxiety symptoms in Parkinson’s disease (2017) (31)
Serotonin and dopamine transporters in relation to neuropsychological functioning, personality traits and mood in young adult healthy subjects (2010) (31)
Subjective experiences during dopamine depletion. (2005) (31)
Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients (2015) (31)
Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria (2017) (31)
Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography (1997) (31)
Incidental Head and Neck Findings on MRI in Young Healthy Volunteers: Prevalence and Clinical Implications (2012) (30)
Early-stage [123I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson’s disease (2005) (30)
Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research (2012) (30)
Reduced striatal brain volumes in non-medicated adult ADHD patients with comorbid cocaine dependence. (2013) (30)
Dopaminergic System Dysfunction in Recreational Dexamphetamine Users (2015) (29)
Diagnostic accuracy of 123 IFP-CIT SPECT in possible dementia with Lewy bodies (2008) (29)
Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls (2016) (29)
Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls (2015) (29)
Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. (2003) (28)
The relationship between the dopaminergic system and depressive symptoms in cervical dystonia (2017) (28)
Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes (2016) (28)
Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis (2014) (28)
Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. (2011) (28)
Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2 (2018) (28)
Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies (2016) (27)
Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. (2005) (27)
Rigidity decreases resting tremor intensity in Parkinson's disease: A [123I]β‐CIT SPECT study in early, nonmedicated patients (2001) (26)
The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI (2014) (26)
Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study (2020) (26)
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. (2009) (26)
BRIEF REPORT: Varenicline increases striatal dopamine D2/3 receptor binding in rats (2009) (25)
Striatal D2receptor binding in 22q11 deletion syndrome: an [123 I]IBZM SPECT study (2010) (25)
Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. (2014) (25)
Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats (2012) (24)
No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT (2013) (24)
The role of molecular imaging in the differential diagnosis of parkinsonism. (2012) (23)
Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis (2016) (23)
Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis☆ (2018) (23)
Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis (2011) (23)
Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats (2011) (23)
Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome (2016) (23)
In vivo [123I]CNS‐1261 binding to D‐serine‐activated and MK801‐blocked NMDA receptors: A storage phosphor imaging study in rats (2009) (23)
Serotonin Transporter Binding in the Diencephalon Is Reduced in Insulin-Resistant Obese Humans (2016) (22)
Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging (2014) (22)
Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence (2013) (22)
The Effects of Ecstasy (MDMA) on Brain Serotonin Transporters Are Dependent on Age-of-First Exposure in Recreational Users and Animals (2012) (22)
Timing of caloric intake during weight loss differentially affects striatal dopamine transporter and thalamic serotonin transporter binding (2017) (21)
[Presymptomatic detection of Parkinson's disease]. (2002) (21)
Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. (1998) (21)
Monoaminergic dysfunction in recreational users of dexamphetamine (2013) (21)
Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging (2018) (21)
Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review (2008) (21)
Deep Brain Stimulation of the Pallidum is Effective and Might Stabilize Striatal D2 Receptor Binding in Myoclonus–Dystonia (2011) (21)
Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms (2017) (21)
FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson ’ s disease (2001) (20)
Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI (2012) (20)
In vitro and in vivo characterization of newly developed iodinated 1‐{2‐[Bis(4‐fluorophenyl)methoxy]ethyl}piperazine derivatives in rats: Limited value as dopamine transporter SPECT ligands (1996) (20)
Reliability and Reproducibility of Neuromelanin‐Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences (2020) (19)
Relationships between Serotonin Transporter Binding in the Raphe Nuclei, Basal Ganglia, and Hippocampus with Clinical Symptoms in Cervical Dystonia: A [11C]DASB Positron Emission Tomography Study (2018) (19)
No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder (2015) (19)
Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone (2019) (19)
SPECT imaging of D2 dopamine receptors and endogenous dopamine release in mice (2008) (19)
Validity of in vivo [123I]β-CIT SPECT in detecting MDMA-induced neurotoxicity in rats (2004) (19)
COMT Val158met genotype and striatal D2/3 receptor binding in adults with 22q11 deletion syndrome (2011) (18)
beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson ' s disease (2003) (18)
3-D Rat Brain Phantom for High-Resolution Molecular Imaging (2009) (18)
Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study (2019) (18)
123I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M1 In Vivo (2015) (18)
No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity (2006) (18)
The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging (2017) (17)
Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor. (2011) (17)
Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder (2014) (17)
Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques (2017) (17)
Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats. (2012) (17)
Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI (2013) (17)
Lower cortisol levels and attenuated cortisol reactivity to daily-life stressors in adults with 22q11.2 deletion syndrome (2019) (16)
Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. (2009) (16)
Autonomic failure in Parkinson’s disease is associated with striatal dopamine deficiencies (2020) (16)
Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. (2006) (16)
Iodine-123 labelled nor-β-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats (1998) (16)
Addition of a 5‐HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP‐CIT binding to dopamine transporters in rat frontal cortex and hippocampus (2001) (16)
Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study (2019) (15)
Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies (2018) (15)
Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression (2014) (15)
Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus (2013) (14)
Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state. (2014) (14)
Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behavior in first-degree relatives of individuals with psychotic disorder (2017) (14)
Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor (2018) (14)
Reactivity to social stress in ethnic minority men (2016) (14)
The effect of the muscarinic M1 receptor antagonist biperiden on cognition in medication free subjects with psychosis (2017) (13)
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine (2013) (13)
18F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure (2017) (13)
Whole-Body 18F-FDG PET-CT in the Diagnosis of Neurosarcoidosis. (2020) (13)
Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity (2018) (13)
Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands (2016) (13)
Bromocriptine and insulin sensitivity in lean and obese subjects (2016) (13)
Psychotic reactions to daily life stress and dopamine function in people with severe hearing impairment (2014) (13)
Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study. (2006) (12)
Striatal dopamine synthesis capacity in autism spectrum disorder and its relation with social defeat: an [18F]-FDOPA PET/CT study (2021) (12)
Subjective experience and striatal dopamine D2 receptor occupancy in patients with recent-onset schizophrenia treated with olanzapine or risperidone (2000) (12)
Investigating serotonergic function using positron emission tomography: overview and recent findings. (2010) (12)
Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD (2014) (12)
Low prevalence of substance use in people with 22q11.2 deletion syndrome (2019) (11)
Quantitative agreement between [15O]H2O PET and model free QUASAR MRI‐derived cerebral blood flow and arterial blood volume (2016) (11)
Cannabinoid‐1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability (2013) (11)
Comparative in vivo study of iodine‐123‐labeled β‐cit and nor‐β‐cit binding to serotonin transporters in rat brain (1999) (11)
Performance evaluation of a novel brain-dedicated SPECT system (2018) (11)
Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. (2005) (11)
New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. (2004) (11)
Affective and psychotic reactivity to daily-life stress in adults with 22q11DS: a study using the experience sampling method (2020) (11)
The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men (2010) (11)
Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway (2011) (11)
Effects of MDMA (ecstasy) use and abstention on serotonin neurons (2002) (11)
SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias (2013) (11)
Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway (2002) (10)
The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease. (2014) (10)
Consistent skin α-synuclein positivity in REM sleep behavior disorder - A two center two-to-four-year follow-up study. (2021) (10)
Imaging as tool to investigate psychoses and antipsychotics. (2012) (10)
The dopaminergic system in patients with functional dyspepsia analysed by single photon emission computed tomography (SPECT) and an alpha-methyl-para-tyrosine (AMPT) challenge test (2011) (10)
Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. (1997) (9)
( 123 I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study (2013) (9)
The response to prolonged fasting in hypothalamic serotonin transporter availability is blunted in obesity (2021) (9)
Striatal dopamine release and impaired reinforcement learning in adults with 22q11.2 deletion syndrome (2018) (9)
Effects of intravenous thyrotropin-releasing hormone on 18F-fluorodeoxyglucose uptake in human brown adipose tissue: a randomized controlled trial. (2018) (9)
Subjective experience and D-2 receptor occupancy in patients with schizophrenia, treated with low dose olanzapine or haloperidol; A randomized double-blind study (2002) (9)
Somatostatin receptor scintigraphy in nasopharyngeal carcinoma. (2008) (9)
Hot heads & cool bodies: The conundrums of human brown adipose tissue (BAT) activity research. (2017) (8)
Brain dopamine and serotonin transporter binding are associated with visual attention bias for food in lean men (2016) (8)
No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats (2008) (8)
Increase in central striatal dopamine transporters in patients with Shwachman–Diamond syndrome: Additional evidence of a brain phenotype (2013) (8)
Tako-tsubo cardiomyopathy: How to understand possible pathophysiological mechanism and the role of 123I-MIBG imaging (2014) (8)
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers (2020) (8)
Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET (2015) (8)
Imaging the addicted brain: reward, craving, and cognitive processes [ch 13] (2005) (8)
Decreased ipsilateral [¹²³I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats. (2014) (7)
Synthesis, biodistribution and PET studies in rats of (18)F-Labeled bridgehead fluoromethyl analogues of WAY-100635. (2012) (7)
Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder (2016) (7)
Interobserver and intraobserver variability for the assessment of brown adipose tissue activity on 18F-FDG PET-CT (2016) (7)
Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate (2017) (7)
Daily-life stress differentially impacts ventral striatal dopaminergic modulation of reward processing in first-degree relatives of individuals with psychosis (2018) (7)
Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis (2018) (7)
[Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines]. (2010) (7)
Acute Administration of Haloperidol Does Not Influence 123I-FP-CIT Binding to the Dopamine Transporter (2014) (6)
Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients (2021) (6)
Dose-dependent effects of the selective serotonin reuptake inhibitor citalopram: A combined SPECT and phMRI study (2019) (6)
Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers (2015) (6)
Striatal Dopamine D-2/3 Receptor Availability in Treatment Resistant Depression (vol 9, e113612, 2014) (2015) (6)
Clinical evaluation of [123I]FP-CIT SPECT scans on the novel brain-dedicated InSPira HD SPECT system: a head-to-head comparison (2018) (6)
Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules (2022) (6)
Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study (2020) (6)
Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M2 receptors with SPET. (2004) (6)
Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD) (2020) (5)
Effect of age and gender on dopamine transporter imaging with [I]FP-CIT SPECT in healthy volunteers (2011) (5)
Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders (2022) (5)
No loss of striatal dopamine transporters and D2 receptors in patients with autosomal recessive dopa-responsive dystonia (1999) (5)
PET and SPECT Imaging of the Central Dopamine System in Humans (2020) (5)
Converging evidence for specific neurotoxic effects of ecstasy on the thalamus (2007) (5)
Serotonin Transporter Availability in Early Stage Parkinson's Disease and Multiple System Atrophy (2014) (5)
Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [123I]FP-CIT SPECT imaging by neurologists in patients with early drug-naive Parkinson’s disease (2019) (5)
dopaminergic degeneration in early stage Parkinson's disease (2006) (5)
Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study (2001) (5)
Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study (2019) (5)
The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial (2020) (4)
Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (European Journal of Nuclear Medicine and Molecular Imaging, (2017), 44, 3, (353-357), 10.1007/s00259-016-3589-9) (2017) (4)
Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern (2021) (4)
[123I]Ioflupane imaging in Caucasians and non-Caucasians: Are there any differences? (2018) (4)
Chapter 4 Reduced striatal D 2 receptor binding in Myoclonus – Dystonia (2011) (4)
Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats (2015) (4)
Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors (2014) (4)
Sleep-Cognition Hypothesis In maritime Pilots, what is the effect of long-term work-related poor sleep on cognition and amyloid accumulation in healthy middle-aged maritime pilots: methodology of a case–control study (2019) (4)
Human in vivo neuroimaging to detect reprogramming of the cerebral immune response following repeated systemic inflammation (2021) (4)
[18F]FES uptake in the pituitary gland and white matter of the brain (2021) (3)
Molecular Imaging of Depressive Disorders (2020) (3)
Functional MR Imaging on an Open 1T MR Imaging System: Exploiting the Advantages of an Open MR Imaging System for Functional MR Imaging (2011) (3)
Clinical Applications of [123I]FP-CIT SPECT Imaging (2014) (3)
Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT. (2011) (3)
Accuracy of possible and probable Alzheimer Disease diagnosis: a methodological comparison using SPM and Principal Component Analysis (2004) (3)
Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study (2019) (3)
Cerebral [18F]-FDOPA Uptake in Autism Spectrum Disorder and Its Association with Autistic Traits (2021) (3)
COMT MET HEMIZYGOTES HAVE LOWER STRIATAL D 2/3 RECEPTOR BINDING THAN VAL HEMIZYGOTES – PRELIMINARY RESULTS IN ADULTS WITH 22Q11 DELETION SYNDROME (2010) (3)
Dopaminergic Effects on Brown Adipose Tissue (DEBAT): A prospective physiological study. (2017) (3)
Effects of average reward rate on vigor as a function of individual variation in striatal dopamine (2021) (3)
The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders (2020) (3)
Obesity an Addiction? Imaging of Neurotransmitter Systems in Obesity (2014) (3)
68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas (2020) (3)
Comments on Eusebio et al.: Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects (2012) (3)
1.018 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study (2007) (2)
Association Tests of Striatal DAT Availability and SNPs That Impact a Novel Splice Variant in the DAT Gene (2012) (2)
Synthesis and in Vitro Evaluation of Bridgehead Fluoromethyl Analogues of N-{ 2-[ 4-( 2-methoxyphenyl ) piperazin-1-yl ] ethyl }-N-( pyridin-2-yl ) cyclohexanecarboxamide ( WAY-100635 ) for the 5-HT 1 A Receptor (2011) (2)
Non-invasive MR assessment of serotonin function: dose-dependent effects of the SSRI citalopram (2018) (2)
P.6.f.005 Prevalence of substance use and the relation with psychosis and catechol-O-methyltransferase in patients with chromosome 22q11 deletion syndrome (2015) (2)
Pharmacokinetics and dosimetry of FP-CIT a new ligand to study the pre-synaptic transporter system (1996) (2)
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder (2022) (2)
Understanding Neuropsychiatric Disorders: Molecular imaging of obsessive–compulsive disorder (2010) (2)
Chapter 5 : Deep Brain Stimulation of the Pallidum is effective and might stabilize striatal dopamine D 2 receptor binding in Myoclonus-Dystonia (2011) (2)
Practical benefit of [ 1231 ] FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson ' s disease (2)
Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis (2016) (2)
The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size (2020) (2)
Early stage CIT SPECT and long- term clinical follow-up in patients with an initial clinical diagnosis of Parkinson's disease (2004) (2)
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET (2021) (2)
Acetylcholine Imaging in Psychosis (2020) (2)
Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism (2005) (2)
The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI (2008) (2)
Evaluation of [18F]AMC-15, [18F]FPr-AMC-13 and [18F]FEt-AMC-13 as candidate dopamine D2/3-agonist radioligands for PET (2013) (2)
Investigating the potential neurotoxicity of ecstacy ( MDMA ) . An imaging approach Reneman (2007) (1)
No change in striatal dopamine transporter density in antipsychotic-naive patients with schizophrenia assessed with 123I-FP-CIT SPECT (2000) (1)
The Relationships between Dopaminergic, Glutamatergic, and Cognitive Functioning in 22q11.2 Deletion Syndrome: A Cross-Sectional, Multimodal 1H-MRS and 18F-Fallypride PET Study (2022) (1)
P.2.c.015 The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI (2008) (1)
Dopamine transporter imaging as an in vivo marker of dopaminergic neurons (2001) (1)
P.5.d.005 Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease (2013) (1)
Association of serotonin transporter (SERT) availability and body mass index (BMI) in healthy Europeans (2012) (1)
Artificial Intelligence-Based Assistance in Clinical 123I-FP-CIT SPECT Scan Interpretation (2021) (1)
Neuroimaging in movement disorders: PET and SPECT [ch.32] (2007) (1)
Striatal Dopamine Transporter Availability Is Not Associated with Food Craving in Lean and Obese Humans; a Molecular Imaging Study (2021) (1)
Clinical benefit of dopamine transporter imaging in movement disorders and dementia (2015) (1)
Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors (2014) (1)
Poster walks (2011) (1)
Effect of long-term sleep disruption on cognitive function and brain amyloid-β accumulation: a case-control study (2020) (1)
Dr. de Haan and Colleagues Reply (2001) (1)
Season and gender modify in-vivo serotonin transporter binding in depressed patients and healthy controls (2008) (1)
SOCIAL EXCLUSION AND SENSITIZATION OF THE DOPAMINE SYSTEM: A [123I]IBZM-SPECT STUDY IN YOUNG ADULTS WITH SERIOUS HEARING IMPAIRMENT (2014) (1)
104. Pharmacokinetics and dosimetry of FP-CIT: A new ligand to study the pre-synaptic dopamine transporter system (1996) (1)
[ I] b -CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease (2003) (1)
Cardiac sympathetic activity in 22q11.2 deletion syndrome. (2016) (1)
Dopamine D 2 receptor blockade in schizophrenia [16] (multiple letters) (2001) (1)
LOWE 123 IFP-CIT BINDING TO THE STRIA AL DOPAMINE TRANSPORTER , BUT NOT TO TH EXTRASTRIATAL SEROTONIN TRANSPORTER , IN PARKINSON ’ S DISEASE COMPARED WITH DEMENTIA WITH LEWY BODIES 3 (2018) (1)
Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings (2022) (1)
Detection of preclinical Parkinson's disease: the olfactory approach (2004) (1)
P.3.b.007 Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behaviour in relatives of individuals with psychotic disorder (2017) (1)
Response to letter: More fat, less migration: breast density as a predictor of sentinel lymph node non-visualization in breast cancer (2021) (1)
Cognitive impairment in early Parkinson's disease: An [123I] FP-CIT SPECT study (2014) (1)
Affective and psychotic reactivity to daily-life stress in adults with 22q11DS: a study using the experience sampling method (2020) (1)
Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients (2015) (1)
PET and SPECT Imaging in Dystonia (2014) (1)
Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning (2021) (1)
University of Groningen Agonist signalling properties of radiotracers used for imaging of dopamine D-2 / 3 receptors (2017) (0)
Dopamine deficiency and clinical symptoms in suspected Lewy body dementia: a quantitative [123I]FP-CIT SPECT study (2014) (0)
UvA-DARE ( Digital Academic Repository ) Demonstration of a reduction in muscarinic receptor binding in early Alzheimer ' s disease using iodine-123 dexetimide single-photon emmission tomography (1997) (0)
P.3.b.026 Differences in cortical morphology between 22q11.2 deletion syndrome patients and patients at ultra-high risk for psychotic disorders (2015) (0)
P.3.b.024 Changes in white matter microstructure integrity of the limbic system after psychosis in 22q11 deletion syndrome seems to be associated with psychosis (2015) (0)
Abstract LB-209: Neuroblastoma is biphasic with classical neuro-epithelial cells and chemoresistant mesenchymal cells controlled by PRRX1-NOTCH signaling (2015) (0)
Focal radiotracer uptake below the bladder in bone scintigraphy is related to the volume of tissue removed by transurethral resection of the prostate (TURP) in patients with known prostate malignancy (2016) (0)
Clinical utility of 18F-FDG PET-CT in the diagnosis of neurosarcoidosis (2017) (0)
E 123 I ] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson ' s disease (2003) (0)
Evidence for absence of links between striatal dopamine synthesis capacity and working memory capacity, spontaneous eye-blink rate, and trait impulsivity (2022) (0)
P.2.c.030 Volumetric changes in amygdala and hippocampus after three months of paroxetine treatment for major depressive disorder (2012) (0)
Radiosynthesis and in vitro evaluation of a series of novel homologous [F-18]-labeled dopamine D-2/3-agonist ligands (2013) (0)
The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists? (2016) (0)
Paraneoplastic Cerebellar Syndrome Presented as Cerebellar Hypermetabolism in a Patient With Occult Breast Carcinoma (2022) (0)
OR19: Striatal Activity Decreases Following the Intragastric Infusion of Glucose and Lipids in Lean Humans (2019) (0)
T138. Serotonin Transporter Occupancy Predicts Default-Mode Network Connectivity: A SPECT and Resting-State fMRI Study (2018) (0)
P.1.g.079 Dopaminergic neurotransmission in clinical and genetic high risk populations for psychosis (2013) (0)
Corrigendum to "Cardiac sympathetic activity in 22q11.2 deletion syndrome" [Int. J. Cardiol. 212 (2016) 346-351]. (2016) (0)
Anatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphy (2022) (0)
626. Reward Learning and Dopamine Release in Adults with 22q11DS: A Study Using [18F]fallypride Positron Emission Tomography (2017) (0)
Poster #T82 SOCIAL STRESS AND PSYCHOTIC SYMPTOMS IN THE DAILY LIFE OF YOUNG ADULTS WITH HEARING IMPAIRMENT (2014) (0)
Olfaction and warly detection of Parkinson's disease. Authors' reply (2005) (0)
Serotonin transporter (SERT) polymorphism modifies the association between SERT occupancy and paroxetine treatment response: A [123I]β-CIT SPECT study (2008) (0)
Sepiapterin reductase de W ciency an autosomal recessive DOPA-responsive dystonia (2006) (0)
Value of Semiquantitative Analysis for Clinical Reporting of 123 I-2-b-Carbomethoxy-3b-(4-Iodophenyl)-N-(3-Fluoropropyl) (2013) (0)
Striatal dopamine and nigral neuromelanin: a multimodal imaging study in schizophrenia and healthy controls (2023) (0)
Pinhole SPECT of dopamine D2 receptors and endogenous dopamine release in mice (2008) (0)
Iodine- 12 3-N- w-F!uoropropyl-2 J3-Carbomethoxy--3f3-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson' s Disease (2006) (0)
S.07.03 Effects of varenicline on dopamine D2/3 receptor binding in rats using ex vivo phosphor storage imaging (2009) (0)
PP013-SUN A HYPERCALORIC HIGH FAT-HIGH SUGAR DIET DECREASES DIENCEPHALIC SEROTONIN TRANSPORTERS IN HUMANS (2012) (0)
Cue-reactivity and craving in heroin dependent patients: a neuroimaging study using both SPECT and fMRI (2003) (0)
I-123-FP-CIT pharmacokinetics and dosimetry show great potential for the evaluation of dopamine transporter system in clinical routine (1996) (0)
UvA-DARE ( Digital Academic Repository ) Neurobiological aspects of obesity : dopamine , serotonin , and imaging (2012) (0)
Voluntary Physical Activity Modulates Self-Selection of a High-Caloric Choice Diet in Male Wistar Rats (2023) (0)
Erratum to: Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database (2013) (0)
The article by Ponsen and colleagues 1 and the accompanying editorial by Stern 2 point out the importance of preclinical detection of risk for subsequent development of Parkinson's (2004) (0)
QT prolongation by dexamphetamine: Does experience matter? (2017) (0)
No difference in 5-HT transporter densities in individuals who stopped using MDMA as compared to controls (2000) (0)
Characterization of 123I-and 18F-labeled radiopharmaceuticals for imaging dopamine D2-receptors in the high-affinity state (2013) (0)
Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study (2020) (0)
CH 1,2, AND 3 BASAL FOREBRAIN NUCLEI VOLUMES PREDICT FUNCTIONAL SENSITIVITY TO MUSCARINIC M1 RECEPTOR ANTAGONIST BIPERIDEN ON DELAYED WORD RECALL (2019) (0)
Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients (2019) (0)
[Progressive supranuclear paralysis; a late diagnosis]. (1995) (0)
Obesity: An Addiction? Imaging of Neurotransmitter Systems in Obesity (2020) (0)
A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice. (2023) (0)
P.1.i.026 Non-invasive magnetic resonance imaging of human serotonin function: dose-dependent effects of citalopram (2017) (0)
Dopamine, Glutamate and the Relation With Cognition in 22q11.2 Deletion Syndrome: A [18F]fallypride Pet and 7-Tesla 1H-MRS Study (2021) (0)
P.4.02 Effects of varenicline on dopamine D2/3 receptor binding in rats using ex vivo phosphor storage imaging (2009) (0)
The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings (2023) (0)
First prospective study on the effects of low doses ecstasy on the brain in new ecstasy users, using a combination of advanced MR imaging techniques and [I-123]beta-CIT SPECT (2007) (0)
Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications (2012) (0)
P.1.i.035 Lower hippocampal muscarinic M1 receptor expression is related to increased hippocampal activation during memory encoding in recent onset psychosis (2016) (0)
Title : QT prolongation by dexamphetamine : Does experience matter ? Short title : QT prolongation by dexamphetamine (2017) (0)
Depression Leading to Attempted Suicide After Bilateral Subthalamic Nucleus Stimulation for Parkinson’s Disease (2002) (0)
Neuromelanin MRI as biomarker for treatment resistance in first episode schizophrenia patients (2022) (0)
PET and SPECT Imaging in Hyperkinetic Movement Disorders (2014) (0)
The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies (2016) (0)
S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY (2018) (0)
The Loss of Extrastriatal As Well As Striatal [I-123]FP-CIT Binding Is More Pronounced in MSA-P and PSP Than in Parkinson's Disease (2016) (0)
ASL based phMRI in assessing serotonergic response in users of XTC (2009) (0)
103. Investigation of the pre-synaptic dopamine transporter system with FP-CIT in normals and patients with Parkinsonʼs disease (1996) (0)
Gallium-68 -DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas (2020) (0)
Reply: Olfaction and early detection of Parkinson's disease (2005) (0)
Su1964 Alterations in the Central Dopaminergic System in Patients With Functional Dyspepsia (2012) (0)
Synthesis And Preliminary Evaluation Of [18F]AMC-20 As Candidate Dopamine D2/3-Agonist Radioligand For PET (2013) (0)
888. Cholinergic Neurotransmission and Cognition in Medication-Free Subjects with Psychosis (2017) (0)
Decrease of amygdala-hyperactivation in MDD is associated with paroxetine SERT-occupancy (2010) (0)
The functional circuits related to serotonin transporter and serotonin 1A receptor are differentially associated to serotonin transporter availability after an acute citalopram challenge (2022) (0)
F142. THE USE OF NEUROIMAGING MARKERS IN STRATIFIED DIAGNOSIS AND THERAPY OF SCHIZOPHRENIC AND AFFECTIVE DISORDERS (2018) (0)
1.113 Hyposmia, cognitive dysfunction and the future risk of Parkinson's disease: A five-year prospective study (2007) (0)
Neuromelanin MRI as Biomarker for Treatment Resistance in First Episode Schizophrenia (2022) (0)
CHAPTER 6 NO SIGNIFICANT EFFECTS OF SINGLE INTRAVENOUS , SINGLE ORAL AND SUB-CHRONIC ORAL ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS ON STRIATAL [ 123 I ] FP-CIT BINDING IN RATS (2008) (0)
SPECT in suspected dementia with Lewy bodies : a longitudinal case study (2013) (0)
IC-P1-041: Predictive diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies: A 12-month follow-up study (2008) (0)
P.523 Neuromelanin MRI as biomarker for treatment resistance in first episode schizophrenia patients (2020) (0)
dementia with Lewy bodies: a longitudinal case study (2013) (0)
Short Communication Comparative In Vivo Study of Iodine-123-Labeled b-CIT and nor-b-CIT Binding to Serotonin Transporters in Rat Brain (1999) (0)
Imaging Dopamine Transporters in a Mouse Brain with Single-Pinhole SPECT (2005) (0)
S.06.04 Dysfunctional reward circuitry in OCD (2011) (0)
P.1.013 The cannabinoid-1 receptor antagonist rimonabant increases striatal dopamine D2/3 receptor availability in rats (2011) (0)
Dopaminergic modulation of reward responses in the striatum of individuals with a genetic risk for psychosis (2016) (0)
Imaging in hepatopulmonary syndrome: a case report. (2015) (0)
Modulation of functional networks related to the serotonin neurotransmitter system by citalopram: evidence from a multimodal neuroimaging study (2023) (0)
P.3.b.023 The effect of the muscarinic M1 receptor antagonist biperiden on cognition in patients with a psychotic disorder and healthy controls (2016) (0)
For peer review only ( 123 I)FP -CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study (2013) (0)
Synthesis and evaluation of [F-18]AMC-13 and [F-18]AMC-15-novel candidate dopamine D-2/3-agonist tracers for positron emission tomography (PET) (2013) (0)
15:30 STARTLE REACTIVITYAND PREPULSE INHIBITION IN SUBJECTS AT ULTRA HIGH RISK FOR PSYCHOSIS: CORRELATION WITH STRIATAL D2/3 RECEPTOR BINDING FOLLOWING DOPAMINE DEPLETION (2012) (0)
P.3.083 Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications (2005) (0)
Long‐term effects of work‐related sleep disruption on cognitive function and brain amyloid‐β load (2020) (0)
The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size (2020) (0)
SYNTHESIS AND IN-VITRO EVALUATION OF NOVEL NORTROPANE DERIVATIVES AS POTENTIAL RADIOTRACERS FOR MUSCARINIC M 2 RECEPTORS (2008) (0)
Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls (2015) (0)
BINDING TO CORTICAL MUSCARINIC RECEPTORS IN UNILATERALLY 6-HYDROXYDOPAMINE LESIONED RATS (2008) (0)
Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings (2014) (0)
Fundamental studies on radiotracers intended for receptor imaging in dementia (2008) (0)
ORIGINAL RESEARCH Functional MR Imaging on an Open 1T MR Imaging System: Exploiting the Advantages of an Open MR Imaging System for Functional MR Imaging (2011) (0)
Clinical and neurophysiological effects of central thalamic deep brain stimulation in the minimally conscious state after severe brain injury (2022) (0)
Clinical and neurophysiological effects of central thalamic deep brain stimulation in the minimally conscious state after severe brain injury (2022) (0)
Reply (2005) (0)
F144. MUSCARINIC M1 RECEPTOR SIGNALLING UNDERLYING COGNITION IN PSYCHOTIC DISORDERS (2018) (0)
No evidence for decreased D2/3 receptor availability and frontal hypoperfusion in subjects with compulsive pornography use (2021) (0)
Synthesis and In Vitro Evaluation of Novel Nortropane Derivatives as Potential Radiotracers for Muscarinic M2 Receptors (2011) (0)
F219. Brain Metabolites and the Relation With Cognition and Psychotic Symptoms in Medication-Free Psychosis and Controls: A Pharmacological Magnetic Resonance Spectroscopy Study (2018) (0)
P.1.29 The decrease of amygdala hyperactivation in depression is associated with paroxetine serotonin transporter occupancy (2009) (0)
Abstract P3-02-11: Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F]FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer (2022) (0)
Preparation of [F-18]4-fluorobutyl tosylate and its use for F-18-fluoroalkylation (2011) (0)
Neuromelanin-sensitive MRI as an alternative biomarker to address dopaminergic abnormalities in schizophrenia – a cross-sectional multimodal imaging study (2022) (0)
Executive functioning and the hypodopaminergic state in adults with phenylketonuria (2016) (0)
Correction: Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression (2015) (0)
Early-stage [I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson’s disease (2005) (0)
Reactivity to Daily Life and Experimental Social Stress in Second-Generation Moroccan-Dutch Men (2015) (0)
Role of cerebral atrophy in the measurement of muscarinic receptor density in patients with Alzheimer's disease (1997) (0)
V.4 DAT-SCAN in Parkinson's Disease and multiple system atrophy/progressive supranuclear palsy (2006) (0)
Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment (2011) (0)
Detection of an undescended parathyroid adenoma with 18F-fluorocholine PET/CT (2022) (0)
TRH and BAT in humans 115 6 (2016) (0)
Neural correlates of ethnic minority position and risk for psychosis (2020) (0)
Iodine-123 and Fluorine-18 labeled radiopharmaceuticals for the visualization of serotonin-1A (5-HT1A) receptors in the central nervous system (2006) (0)
Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome (2022) (0)
Striatal dopamine transporter availability and body mass index in a large European sample of healthy subjects (2012) (0)
Acceleration of neuromelanin-sensitive MRI sequences in the substantia nigra using standard MRI options (2022) (0)
risperidone in young patients with schizophrenia (1999) (0)
P.4.f.004 Deep brain stimulation in obsessive–compulsive disorder induces striatal dopamine release (2013) (0)
P.3.b.049 Cholinergic neurotransmission and cognition in medication-free subjects with psychosis (2017) (0)
1.270 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study (2007) (0)
P1-273: Predictive diagnostic accuracy of 123I-FP-CIT spect in possible dementia with Lewy bodies: A 12-month follow-up study (2008) (0)
10. Muscarinic M1 Receptor Binding and Cognition in Medication Free Subjects with Psychosis (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jan Booij?

Jan Booij is affiliated with the following schools:

University of Amsterdam

Jan Booij's Academic­Influence.com Rankings